Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2019 | Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

Othman Al-Sawaf • 16 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Chlorambucil Obinutuzumab Venetoclax
CLL14

Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, talks about venetoclax plus obinutuzumab in CKT CLL. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Othman Al-Sawaf

CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
9:23
CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
Othman Al-Sawaf • 6 Dec 2025
Treatment of Richter’s transformation: recent insights
1:47
Treatment of Richter’s transformation: recent insights
Othman Al-Sawaf • 16 Jun 2023
The expanding landscape of next-generation BTK inhibitors in CLL
1:26
The expanding landscape of next-generation BTK inhibitors in CLL
Othman Al-Sawaf • 16 Jun 2023
Fixed-duration treatment strategies for frontline and relapsed CLL
0:56
Fixed-duration treatment strategies for frontline and relapsed CLL
Othman Al-Sawaf • 16 Jun 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Othman Al-Sawaf • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Othman Al-Sawaf • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Othman Al-Sawaf • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Othman Al-Sawaf • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals